Assessment of Vaccine Herd Protection: Lessons Learned From Cholera and Typhoid Vaccine Trials.
cholera
oral cholera vaccine
typhoid fever
typhoid vaccine
vaccine herd protection
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
20 12 2021
20 12 2021
Historique:
pubmed:
18
7
2021
medline:
27
1
2022
entrez:
17
7
2021
Statut:
ppublish
Résumé
Vaccine herd protection is the extension of the defense conferred by immunization beyond the vaccinated to unvaccinated persons in a population, as well as the enhancement of the protection among the vaccinated, due to vaccination of the surrounding population. Vaccine herd protection has traditionally been inferred from observations of disease trends after inclusion of a vaccine in national immunization schedules. Rather than awaiting outcomes of widescale vaccine deployment, earlier-stage evaluation of vaccine herd protection during trials or mass vaccination projects could help inform policy decisions about potential vaccine introduction. We describe the components, influencing factors, and implications of vaccine herd protection and discuss various methods for assessing herd protection, using examples from cholera and typhoid vaccine studies.
Identifiants
pubmed: 34273168
pii: 6323356
doi: 10.1093/infdis/jiab358
pmc: PMC8687079
doi:
Substances chimiques
Cholera Vaccines
0
Typhoid-Paratyphoid Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
S764-S769Informations de copyright
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Value Health. 2009 Sep;12(6):899-908
pubmed: 19824189
Stat Methods Med Res. 2000 Apr;9(2):95-116
pubmed: 10946429
Am J Epidemiol. 1997 Nov 15;146(10):789-803
pubmed: 9384199
Lancet Infect Dis. 2019 Jan;19(1):e26-e30
pubmed: 30170987
Sci Rep. 2020 Nov 4;10(1):18977
pubmed: 33149149
Lancet Infect Dis. 2011 Jun;11(6):482-7
pubmed: 21616458
Pediatr Infect Dis J. 2004 Feb;23(2):127-31
pubmed: 14872178
Vaccine. 2012 Aug 3;30(36):5389-95
pubmed: 22721899
Am J Epidemiol. 1999 Nov 15;150(10):1001-21
pubmed: 10568615
JAMA. 2005 Jul 13;294(2):202-10
pubmed: 16014594
Emerg Infect Dis. 2016 Jun;22(6):1067-70
pubmed: 27192187
Wkly Epidemiol Rec. ;92(34):477-98
pubmed: 28845659
Int Health. 2020 Jan 1;12(1):36-42
pubmed: 31608962
Pediatrics. 1991 Feb;87(2):166-70
pubmed: 1846236
Am J Epidemiol. 1991 Feb 15;133(4):323-31
pubmed: 1899778
JAMA. 2006 Apr 12;295(14):1668-74
pubmed: 16609088
Clin Infect Dis. 2011 Apr 1;52(7):911-6
pubmed: 21427399
Lancet. 2005 Jul 2-8;366(9479):44-9
pubmed: 15993232
Proc Biol Sci. 2017 Mar 29;284(1851):
pubmed: 28356449
Pediatr Infect Dis J. 2008 Jan;27(1):33-7
pubmed: 18162935
Am J Public Health. 2004 Mar;94(3):416-22
pubmed: 14998805
J R Soc Med. 2015 May;108(5):192-8
pubmed: 26022551
Stat Med. 1998 May 30;17(10):1121-36
pubmed: 9618773
Clin Infect Dis. 2011 Jan 15;52(2):157-62
pubmed: 21288837
Am J Epidemiol. 1981 Dec;114(6):906-14
pubmed: 7315838
Epidemiol Rev. 1993;15(2):265-302
pubmed: 8174658
mBio. 2011 Jan 25;2(1):e00309-10
pubmed: 21264063
Nat Rev Immunol. 2021 Feb;21(2):83-100
pubmed: 33353987
J Infect Dis. 2018 Oct 15;218(suppl_3):S165-S166
pubmed: 30239901
N Engl J Med. 2009 Jul 23;361(4):335-44
pubmed: 19625715
Lancet. 2005 Jul 9-15;366(9480):144-50
pubmed: 16005337
Lancet Infect Dis. 2012 Nov;12(11):837-44
pubmed: 22954655
PLoS Med. 2007 Nov 27;4(11):e336
pubmed: 18044983
Front Public Health. 2019 Jul 31;7:211
pubmed: 31417890